Annual SG&A
$19.06 M
+$1.50 M+8.55%
31 December 2023
Summary:
Lyra Therapeutics annual selling, general & administrative expenses is currently $19.06 million, with the most recent change of +$1.50 million (+8.55%) on 31 December 2023. During the last 3 years, it has risen by +$9.37 million (+96.73%). LYRA annual SG&A is now at all-time high.LYRA Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$3.93 M
-$1.21 M-23.51%
30 September 2024
Summary:
Lyra Therapeutics quarterly selling, general & administrative expenses is currently $3.93 million, with the most recent change of -$1.21 million (-23.51%) on 30 September 2024. Over the past year, it has dropped by -$1.07 million (-21.43%). LYRA quarterly SG&A is now -32.43% below its all-time high of $5.82 million, reached on 31 March 2024.LYRA Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$1.42 B
-$97.61 M-7.38%
30 September 2024
Summary:
Lyra Therapeutics TTM selling, general & administrative expenses is currently -$1.42 billion, with the most recent change of -$97.61 million (-7.38%) on 30 September 2024. Over the past year, it has dropped by -$1.44 billion (-7539.71%). LYRA TTM SG&A is now -1012.20% below its all-time high of $20.32 million, reached on 30 June 2024.LYRA TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LYRA Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +8.6% | -21.4% | -7539.7% |
| 3 y3 years | +96.7% | -2.2% | -10000.0% |
| 5 y5 years | +440.2% | +183.8% | -10000.0% |
LYRA Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +96.7% | -32.4% | +10.2% | -116.6% | at low |
| 5 y | 5 years | at high | +440.2% | -32.4% | +206.2% | -1012.2% | at low |
| alltime | all time | at high | +440.2% | -32.4% | +357.1% | -1012.2% | at low |
Lyra Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $3.93 M(-23.5%) | $19.25 M(-5.3%) |
| June 2024 | - | $5.14 M(-11.7%) | $20.32 M(+2.9%) |
| Mar 2024 | - | $5.82 M(+33.5%) | $19.75 M(+3.6%) |
| Dec 2023 | $19.06 M(+8.5%) | $4.36 M(-12.9%) | $19.06 M(-0.2%) |
| Sept 2023 | - | $5.00 M(+9.5%) | $19.10 M(-0.7%) |
| June 2023 | - | $4.57 M(-10.9%) | $19.23 M(+2.3%) |
| Mar 2023 | - | $5.13 M(+16.5%) | $18.80 M(+7.1%) |
| Dec 2022 | $17.56 M(+23.6%) | $4.40 M(-14.4%) | $17.56 M(+5.0%) |
| Sept 2022 | - | $5.14 M(+24.3%) | $16.72 M(+7.2%) |
| June 2022 | - | $4.13 M(+6.3%) | $15.61 M(+3.8%) |
| Mar 2022 | - | $3.89 M(+9.0%) | $15.03 M(+5.8%) |
| Dec 2021 | $14.21 M | $3.57 M(-11.2%) | $14.21 M(+1.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2021 | - | $4.02 M(+12.9%) | $13.95 M(+10.9%) |
| June 2021 | - | $3.56 M(+16.3%) | $12.58 M(+9.8%) |
| Mar 2021 | - | $3.06 M(-7.5%) | $11.46 M(+18.3%) |
| Dec 2020 | $9.69 M(+115.9%) | $3.31 M(+24.9%) | $9.69 M(+24.9%) |
| Sept 2020 | - | $2.65 M(+8.6%) | $7.75 M(+19.5%) |
| June 2020 | - | $2.44 M(+90.2%) | $6.49 M(+32.1%) |
| Mar 2020 | - | $1.28 M(-6.8%) | $4.91 M(+9.4%) |
| Dec 2019 | $4.49 M(+27.2%) | $1.38 M(-0.6%) | $4.49 M(+44.3%) |
| Sept 2019 | - | $1.39 M(+60.1%) | $3.11 M(+80.3%) |
| June 2019 | - | $865.00 K(+0.6%) | $1.73 M(+100.6%) |
| Mar 2019 | - | $860.00 K | $860.00 K |
| Dec 2018 | $3.53 M | - | - |
FAQ
- What is Lyra Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Lyra Therapeutics?
- What is Lyra Therapeutics annual SG&A year-on-year change?
- What is Lyra Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Lyra Therapeutics?
- What is Lyra Therapeutics quarterly SG&A year-on-year change?
- What is Lyra Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Lyra Therapeutics?
- What is Lyra Therapeutics TTM SG&A year-on-year change?
What is Lyra Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of LYRA is $19.06 M
What is the all time high annual SG&A for Lyra Therapeutics?
Lyra Therapeutics all-time high annual selling, general & administrative expenses is $19.06 M
What is Lyra Therapeutics annual SG&A year-on-year change?
Over the past year, LYRA annual selling, general & administrative expenses has changed by +$1.50 M (+8.55%)
What is Lyra Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of LYRA is $3.93 M
What is the all time high quarterly SG&A for Lyra Therapeutics?
Lyra Therapeutics all-time high quarterly selling, general & administrative expenses is $5.82 M
What is Lyra Therapeutics quarterly SG&A year-on-year change?
Over the past year, LYRA quarterly selling, general & administrative expenses has changed by -$1.07 M (-21.43%)
What is Lyra Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of LYRA is -$1.42 B
What is the all time high TTM SG&A for Lyra Therapeutics?
Lyra Therapeutics all-time high TTM selling, general & administrative expenses is $20.32 M
What is Lyra Therapeutics TTM SG&A year-on-year change?
Over the past year, LYRA TTM selling, general & administrative expenses has changed by -$1.44 B (-7539.71%)